Compare Summit Therapeutics Inc (SMMT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Wheaton Precious Metals Corp trades at $138.57 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 4.5× Summit Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Wheaton Precious Metals Corp for 66 Days on average.
| SMMT | WPM | |
|---|---|---|
Market Cap | $13.71B | $61.17B |
Volume | 6,173,057 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $26.38 | $165.72 |
52-Week Low | $12.43 | $94.37 |
Typical Hold Time | 16 Days | 66 Days |
Enterprise Value | $13.04B | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
WPM trades at $138.65, up 3.71% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported record 2025 revenue of $2.31B and net income of $1.47B, with earnings beating estimates in recent quarters. Analyst consensus is strongly bullish with an 80% buy rating and a $164.80 price target. Recent news highlights production growth targets of 1.2M ounces by 2030 and a fully funded pipeline.
The outlook for WPM is positive given robust earnings growth, high profitability margins, and strategic expansion plans. Key risks include execution of growth targets, commodity price volatility, and interest rate sensitivity. The stock offers upside to consensus targets but faces technical resistance near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
